Revelation Biosciences In... (REVB)
| Bid | 2.92 |
| Market Cap | 2.79M |
| Revenue (ttm) | 26.96K |
| Net Income (ttm) | -15.04B |
| EPS (ttm) | -90.02 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | -1.06 |
| Analyst | n/a |
| Ask | 3.35 |
| Volume | 11,058 |
| Avg. Volume (20D) | 158,093 |
| Open | 3.04 |
| Previous Close | 3.00 |
| Day's Range | 2.94 - 3.12 |
| 52-Week Range | 2.36 - 60.80 |
| Beta | 0.24 |
About REVB
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is a...
1 month ago · businesswire.com
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth ConferenceSAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...
1 month ago · businesswire.com
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing ApprovalSAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflamm...
